Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iron lung

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    116 result(s) found for: Iron lung. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-002366-39 Sponsor Protocol Number: 000000 Start Date*: 2018-08-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: A pilot trial of intravenous iron for the treatment of iron deficiency in adult patients with cystic fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-000130-33 Sponsor Protocol Number: ORION-HF Start Date*: 2022-12-23
    Sponsor Name:Hannover Medical School
    Full Title: A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)
    Medical condition: Patients with heart failure, iron deficiency and anaemia with either reduced or preserved left ventricular ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 100000004849 10024106 Left heart failure LLT
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001238-89 Sponsor Protocol Number: FACE Start Date*: 2016-06-15
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: IRON DEFICIENCY IN PATIENTS WITH COPD: IMPACT OF TOPPING WITH IRON CARBOXYMALTOSE. FACE STUDY (ASSESSMENT IN PATIENTS WITH FERINJECT AND IRON DEFICIENCY COPD TO IMPROVE EXERCISE TOLERANCE)
    Medical condition: Iron deficiency in Chronic obstructive pulmonary disease patients (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002952-17 Sponsor Protocol Number: COPDIron Start Date*: 2012-11-12
    Sponsor Name:University of Oxford
    Full Title: Effects of intravenous iron on hypoxic pulmonary responses in COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000829-39 Sponsor Protocol Number: 2016LF003B Start Date*: 2016-11-10
    Sponsor Name:Royal Brompton and Harefiled NHS Foundation Trust, Royal Brompton Hospital
    Full Title: Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003659-52 Sponsor Protocol Number: PULSE Start Date*: 2018-04-02
    Sponsor Name:António Robalo Nunes
    Full Title: Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease: an open-label, randomized, 2-arm, no treatment control, parallel s...
    Medical condition: Chronic Obstructive Pulmonary Disease and Iron Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-005005-43 Sponsor Protocol Number: FACEII Start Date*: 2022-06-06
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona
    Full Title: Ferinject in Addition to pulmonary rehabilitation in patients with COPD and iron deficiency to improve Exercise tolerance (FACE II study)
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000634-11 Sponsor Protocol Number: MEK114653 Start Date*: 2011-07-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) i...
    Medical condition: In 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC Stage IIIBwet-IV).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Temporarily Halted) NL (Prematurely Ended) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-000779-40 Sponsor Protocol Number: VEG109611 Start Date*: 2008-07-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC)
    Medical condition: Relapsed or Refractory Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007520-17 Sponsor Protocol Number: 800088NAP2001 Start Date*: 2008-07-25
    Sponsor Name:Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thromb...
    Medical condition: Chemotherapy induced anaemia and chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10039884 Secondary thrombocytopenia LLT
    9.1 10054606 Secondary anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002472-34 Sponsor Protocol Number: EGF109462 Start Date*: 2007-08-06
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
    Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000927-42 Sponsor Protocol Number: HZC116601 Start Date*: 2012-10-19
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Da...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003510-41 Sponsor Protocol Number: 200163 Start Date*: 2014-01-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-004865-10 Sponsor Protocol Number: SFA100062 Start Date*: 2016-12-08
    Sponsor Name:GlaxoSmithKiline Research and Development LTD.
    Full Title: A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003106-27 Sponsor Protocol Number: RLV116974 Start Date*: 2012-11-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004298-28 Sponsor Protocol Number: MEA117106 Start Date*: 2014-05-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) IT (Completed) BE (Completed) ES (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000884-42 Sponsor Protocol Number: 201316 Start Date*: 2014-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000643-33 Sponsor Protocol Number: TFR116341 Start Date*: 2014-08-26
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery.
    Medical condition: Prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) and other acute inflammatory conditions
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10069351 Acute lung injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002452-13 Sponsor Protocol Number: HZC115151 Start Date*: 2012-01-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhale...
    Medical condition: Subjects with Chronic Obstructive Pulmonary Disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:28:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA